LONDON--(BUSINESS WIRE)-- <\/p>\n
Due to a number of factors like new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; as well as intensifying competition, the clinical chemistry and immunodiagnostics markets are undergoing significant changes. Some segments, such as routine chemistry, start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. All these upcoming transformations in the marketplace are expected to provide amazing opportunities for a variety of new instruments and reagent systems, as well as auxiliary products, like specimen preparation devices, controls, calibrators. <\/p>\n
New research report The 2012 European Clinical Chemistry and Immunodiagnostics Markets: France, Germany, Italy, Spain, UK - Emerging Opportunities and Business Expansion Strategies developed by Venture Planning Group (VPG) explores future marketing and technological trends in five major Europeancountries (France, Germany, Italy, Spain and the UK) and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles top market players; and identifies specific product and marketing opportunities facing suppliers during the next five years. <\/p>\n
Companies mentioned in the report include: Abbott Laboratories, AdnaGen, Ambrilia, AMDL, Beckman Coulter, Biomedical Diagnostics, BioMerieux, Bio-Rad, Canag Diagnostics, Dako, DiaSorin, Eiken, Fujirebio, Instrumentation Laboratory, J&J, Kyowa Medex, Matritech, Roche, Siemens, Sysmex, Thermo Fisher, Trinity Biotech, Tosoh, Wako, and Wallac. <\/p>\n
Report Details: <\/p>\n
Title: The 2012 European Clinical Chemistry and Immunodiagnostics Markets: France, Germany, Italy, Spain, UK - Emerging Opportunities and Business Expansion Strategies Published: March, 2012 Pages: 900 Price: US$ 18,500 <\/p>\n
http:\/\/marketpublishers.com\/report\/medicine_pharmaceuticals_biotechnology\/drugs_biotechnology\/2012_european_clinical_chemistry_n_immunodiagnostics_markets_france_germany_italy_spain_uk_emerging_opportunities_n_business_expansion_strategies.html<\/a> <\/p>\n Report Contents: <\/p>\n INTRODUCTION <\/p>\n WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW A. Major Routine Chemistry Tests 1. Albumin 2. Alkaline Phosphatase 3. ALT\/SGPT 4. Ammonia 5. Amylase 6. AST\/SGOT 7. Bilirubin 8. Blood Gases 9. Blood Urea Nitrogen (BUN) 10. Calcium 11. Cholesterol 12. Cholinesterase 13. Creatinine 14. Electrolytes a. Carbon Dioxide\/Bicarbonate b. Chloride c. Potassium d. Sodium 15. Fructosamine 16. Gamma-Glutamyl Transpeptidase (GGT) 17. Glucose 18. High Density Lipoprotein (HDL) 19. Iron 20. Lactate Dehydrogenase (LDH) 21. Magnesium 22. Phosphorus 23. Protein 24. Triglycerides <\/p>\n<\/p>\n Read the original here: LONDON--(BUSINESS WIRE)-- Due to a number of factors like new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; as well as intensifying competition, the clinical chemistry and immunodiagnostics markets are undergoing significant changes. Some segments, such as routine chemistry, start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. Continue reading
\nEurope Clinical Chemistry & Immunodiagnostics Markets Discussed in New Report Published at MarketPublishers.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"